Dramatic response of aneurysmal bone cyst to denosumab: Case report and literature review

Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor‐kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.

Detalles Bibliográficos
Autores principales: Fadavi, Pedram, Arefpour, Amir Mohammad, Hariri, Ramyar, Vasheghani, Maryam, Garousi, Maryam, Taghizadeh‐Hesary, Farzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548816/
https://www.ncbi.nlm.nih.gov/pubmed/34745616
http://dx.doi.org/10.1002/ccr3.4993
Descripción
Sumario:Denosumab, a monoclonal antibody that specifically targets cytokine receptor activator of nuclear factor‐kappa B ligand (RANKL), is a potentially viable option in resistant aneurysmal bone cysts.

Ejemplares similares